Silence Therapeutics plc (SLNCF) Free cash flow 2022–2025
Silence Therapeutics plc (SLNCF) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$62.3MFY2025 · since FY2022: -$57.2M → -$62.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$62.3M | +8.1% |
| FY2024 | -$67.9M | -37.0% |
| FY2023 | -$49.5M | +13.5% |
| FY2022 | -$57.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SLNCF financial trends
SLNCF RevenueSLNCF Net incomeSLNCF Net marginSLNCF Gross profitSLNCF Gross marginSLNCF Operating incomeSLNCF Operating marginSLNCF Operating cash flowSLNCF Capital expendituresSLNCF Return on equitySLNCF Stock buybacksSLNCF Dividends paidSLNCF Total assetsSLNCF Total liabilitiesSLNCF Shareholders’ equitySLNCF overview →